Please login to the form below
Ranbaxy
This page shows the latest Ranbaxy news and features for those working in and with pharma, biotech and healthcare.
Nearly half of all clinical trials not published
Drilling down into the data provides a mixed picture for the pharma industry - at one end of the scale is Ranbaxy, which has published no results for any of the 35
Latest news
-
Lundbeck challenge to EC pay-for-delay ruling fails
The four generics companies - Generics UK, Arrow, Alpharma and Ranbaxy - were fined around 52m, and those judgments have also been upheld by the General Court of the EU.
-
India denies Vertex patent on cystic fibrosis drug Orkambi
The patent was opposed by the Indian Pharmaceutical Alliance (IPA), a trade organisation representing India's larger pharmaceutical companies, including Cipla, Dr Reddy's Labs, Lupin, Nicholas Piramal, Ranbaxy and Wockhardt.
-
Heart drug sales continue downward spiral
The Swiss firm has managed to delay some generic forms of its drug onto the market until last year, when Ranbaxy was granted approval to sell its copycat form of valsartan.
-
Takeda to pay $2.4bn to settle Actos cancer suits
Actos has generated more than $16bn in sales since its 1999 release, according to court filings, but now also faces generic competition from India's Ranbaxy Laboratories.
-
Teva slapped with $512m fine on pay-for-delay deal
Ranbaxy Laboratories. ... Mylan and Ranbaxy, which are also defendants in the case, are not part of the settlement.
More from news
Approximately 6 fully matching, plus 92 partially matching documents found.
Latest Intelligence
-
Pharma deals in April 2015
The acquisition of this portfolio with sales of INR 150 Crores, will help Dr Reddy's maintain a competitive edge with fellow Indian rival Sun Pharmaceuticals, following its acquisition of Ranbaxy
-
Allergan and taking a specialised approach
But for the likes of GSK, Novartis and Lilly with their asset swap agreement, Forest Laboratories and its acquisition of Actavis, and the various dealings at Merck &Co, BMS, Ranbaxy and
-
Pharma deals during April 2014
for its stake in Ranbaxy in 2008, not to mention the 2013 $500m payment to the US authorities to settle 7 felony charges. ... is rumoured that a solution will be to replace the Ranbaxy brand with the Sun Pharma moniker at least in the US.
-
Deal Watch table for April 2014
Ranbaxy Laboratories/ Sun Pharmaceuticals. Acquisition. Generics including Lipitor, Nexium, Diovan. 3, 200.
-
Positive prospects for pharma in Latin America
Since 2008, more foreign companies such as Takeda, Daiichi Ranbaxy and others have been allowed to set operations in the country, increasing competition and consolidation.
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
Competition from within
Teva (Israel), CSL (Australia) and Aspen (South Africa) are notable exceptions, with the Indian generic giants Sun and Ranbaxy - which have since merged - the only representation from the ‘BRIC’ markets (Brazil,
-
Exploring MINT: Part 3 - Nigeria
as Indian Cipla, Hetero and Ranbaxy among those supplying low-cost generic ARVs to African governments.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Account Supervisor – Leading Healthcare Advertising Agency – New...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Senior Medical Writer – Creative Healthcare Advertising – New Yo...
-
Highly Competitive Salary, Bonus &Benefits
- First trial of a vaccine against Alzheimer’s launches
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- Gilead to pay $745m for three oncology programmes from Arcus Biosciences
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
- Lucid Group: Orange the World
- First trial of a vaccine against Alzheimer’s launches
- New COVID variant causing concern
- PMEA 2021: A Celebration of Excellence in Patient Engagement
- From Academics to Entrepreneurship: How Tech is Revolutionizing the Diagnostics Landscape
- Impetus Digital wins Canada’s Most Admired Corporate Cultures Awards 2021
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Biogen’s Aduhelm unlikely to get approval in Europe
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- The pandemic preparedness paradox
- First trial of a vaccine against Alzheimer’s launches
- Good NICE news for Pfizer, but Dendreon drug rejected
PMHub
Visformatics (VISFO)
A team of strategic decision specialists with over 30+ years in the pharma space, we give you confidence through experience....
Latest intelligence
- Webinar:
- Securing a future for telehealth with immersive market research insights...
- Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
- How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
- Six ways to improve diversity in clinical trials
- Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...
